Loading…
← CockpitCompetitor Analysis › 600557.SS Jiangsu Kanion Pharmaceutical Co. Ltd. Class AOpen in the cockpit ↗

Jiangsu Kanion Pharmaceutical Co. Ltd. Class A600557.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 80
Mkt cap
$989M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$10.7M
20-day average traded
Fwd P/E
19.8×
forward earnings
ROIC−WACC
+2.5 pp
WACC 6.7%
Hurdle
+0 pp
Req g minus delivered
Next earnings
138 days
5 Apr 2027
Close · CNYCN¥12.00
1D-1.1%
1W-2.8%
1M-4.5%
3M-6.8%
6M-8.7%
YTD-14.9%
1Y-19.2%
ATR %2.4%
52w lowhigh27.8% off high

What Jiangsu Kanion Pharmaceutical does

Employees: 5,379

Jiangsu Kanion Pharmaceutical at a glance

Size Jiangsu Kanion Pharmaceutical (600557.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $989M, the 2179th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.00 on 18 Nov 2026.

Performance Over six months the shares fell 8.7%, against -17.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 8.3% over the last twelve months (peer median +9.2%); the operating margin is 7.4% (peer median 12.5%).

Valuation It trades at 19.8× forward earnings against a peer median of 21.4× (8th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.5 points above its cost of capital (6.7% WACC).

Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026600557.SS 94Peer median 86
Six months, rebased to 100: Jiangsu Kanion Pharmaceutical against the median of its 20 peers (local-currency closes).

Jiangsu Kanion Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.37BCN¥3.27BCN¥3.86BCN¥4.81BCN¥4.28B
Revenue growth—-15%-20%+12%—
Gross profitCN¥2.58BCN¥2.28BCN¥2.72BCN¥3.46BCN¥2.99B
EBITDAn/aCN¥448MCN¥497MCN¥610MCN¥592M
Net incomeCN¥316MCN¥304MCN¥392MCN¥464MCN¥434M
Free cash flowCN¥15.8MCN¥99.1MCN¥248MCN¥676MCN¥789M
Capital expenditureCN¥603MCN¥522MCN¥477MCN¥311MCN¥211M
Total debtCN¥33.1MCN¥407MCN¥548MCN¥471MCN¥11.9M

Quarterly statements and history in the cockpit →

Jiangsu Kanion Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%AARTIPHARM688382600129SPTXPGHL6887106051166880914565488700065030070268875930029430049768851320054553603538600557.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Kanion Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×600129PGHL68871060511645654887000650300702300294300497688513STAR4553603538600557.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Kanion Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%688382PGHL68871060511645650006503007023004972005STAR4553603538600557.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiangsu Kanion Pharmaceutical is the large dot.

Jiangsu Kanion Pharmaceutical competitors and peer comparison

How Jiangsu Kanion Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Kanion Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600557.SSPeer medianRank in peer set
1-month return-4.5%-7.6%6th highest of 21
6-month return-8.7%-17.5%8th highest of 21
Distance from 52-week high-27.8%-33.9%8th highest of 21
Revenue growth (TTM)+8.3%+9.2%10th highest of 19
Operating margin7.4%12.5%6th lowest of 19
Forward P/E19.8×21.4×8th cheapest of 16
Growth the price implies (Req g, 7 yrs)2.3%5.6%4th least demanding of 14
Growth delivered (Del g)+1.8%+7.7%5th lowest of 14
Hurdle (Req g minus delivered)+0.5 pp-3.3 pp7th most demanding of 14
ROIC minus cost of capital+2.5 pp-0.4 pp7th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%

Questions

Which companies are Jiangsu Kanion Pharmaceutical's closest peers?
The cockpit's peer set: Aarti Pharmalabs (AARTIPHARM.NS), InventisBio (688382.SS), Chongqing Taiji Industry (Group) (600129.SS), Seaport Therapeutics (SPTX), Procter & Gamble Health (PGHL.NS), Shanghai InnoStar Bio-tech (688710.SS), Aurisco Pharmaceutical (605116.SS), Shanghai Yizhong Pharmaceutical (688091.SS).
Is Jiangsu Kanion Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 19.8× against a peer median of 21.4×, 8th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jiangsu Kanion Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -8.7% against -17.5% for the median peer; over one year -19.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.